Cover Story
In a 6-6 vote, ODAC says “maybe” to Sutent for adjuvant kidney cancer—
But at FDA “Maybe” has meaningWith frustrating photo finish voting results—6-6—still on the screen, FDA's cancer czar Richard Pazdur delivered an acerbic thank-you to members of the agency's Oncologic Drugs Advisory Committee:“Well, that's the end vote, it makes our job definitely easier,” said Pazdur, director of the FDA's Oncology Center of Excellence, who gets sarcastic sometimes.
In Brief
Drugs & Targets
Trending Stories
- Gynecology’s deadly surprise:
Cancers are frequently missed prior to routine procedures - Amy Reed, physician and patient who “moved mountains” to end widespread use of power morcellation, dies at 44
- Rathmell announces new cancer screening network, new NCI virtual clinical trials office
- How Beth Carner went from six weeks left to live with stage 4 colon cancer to complete remission
- ASCO 2024 special awards go to: Winn, Bhatia, Dale, Siu, Pierce, Kantoff, Newman, Gopal, Mutebi, Feldman, Gorlick, Pietenpol, Abrahm, Giordano, Vaz-Luis
- Weeks before death from sarcoma, Norm Coleman reflected on his career in radiation oncology and addressing health disparities